Skip to main content

Abbott Laboratories

ABT
Exchange
NYSE
Industry
Pharmaceutical Preparations
SEC CIK
0000001800

In the last 90 days, Abbott Laboratories insiders filed 0 open-market purchases and 3 sales; 2,985 institutions reported holding it in 13F filings for Q2 2026, worth $125.5B in total; 3 superinvestors hold it, including Southeastern Asset Management (Longleaf) and Soros Fund Management.

Key figures

Insider buysOpen market, last 90 days
0
Insider sellsLast 90 days, $46.9M in total
3
13F holdersQ2 2026, −90 vs. previous quarter
2,985
13F valueReported value at the end of Q2 2026
$125.5B
Superinvestors holdingAt the end of Q2 2026
3

Price chart

Superinvestors holding ABT, Q2 2026

3 superinvestors report holding Abbott Laboratories on Form 13F. Percentages are the stock's share of each portfolio.

Go to the superinvestors tab

Southeastern Asset Management (Longleaf)

Mason Hawkins

4.0%

Abbott Laboratories's share of the portfolio

Shares
840,747
Value
$76.3M

Soros Fund Management

George Soros

0.1%

Abbott Laboratories's share of the portfolio

Shares
44,750
Value
$4.06M
Other superinvestors holding ABT (part 1)
SuperinvestorWeightValue
Gardner Russo & Quinn<0.1%$1.04M

Latest insider trades

Open-market purchases and sales by Abbott Laboratories insiders from Form 4, newest first.

See all insider trades
Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Sep 3, 2026 (view filing)6:11 PM ETSep 21 dayMcCoy John A. Jr.VICE PRESIDENT AND CONTROLLERSSaleCommon shares without par value−27$109.54−$2.96K−0.1%24.5K after
Aug 27, 2026 (view filing)5:09 PM ETAug 252 daysFord Robert BCHAIRMAN AND CEOSSaleCommon shares without par value−398.8K$115.85−$46.2M−56.5%306.5K after2 lots
Aug 13, 2026 (view filing)5:14 PM ETAug 112 daysMorrone Louis H.EXECUTIVE VICE PRESIDENTSSaleCommon shares without par value−5.85K$109.83−$642.5K−7.6%70.7K after
Jun 18, 2026 (view filing)May 742 daysLateStratton John GDirectorPPurchaseCommon shares without par value+2.00K$86.82+$173.6K+9.4%23.3K after
Apr 28, 2026 (view filing)Apr 271 dayStarks Daniel JDirectorPPurchaseCommon shares without par value+10.0K$92.65+$926.5K+0.1%6.75M after
Apr 27, 2026 (view filing)Apr 234 daysBoudreau Philip PEVP AND CFOPPurchaseCommon shares without par value+2.20K$91.50+$201.3KNew position2.20K after
Mar 3, 2026 (view filing)Mar 21 dayCushman Elizabeth C.EVP, GC AND SECRETARYSSaleCommon shares without par value−263$115.58−$30.4K−0.7%38.6K after
Mar 3, 2026 (view filing)Mar 21 dayShroff EricSenior Vice PresidentSSaleCommon shares without par value−709$115.58−$81.9K−1.8%39.2K after
Mar 3, 2026 (view filing)Mar 21 dayMorrone Louis H.EXECUTIVE VICE PRESIDENTSSaleCommon shares without par value−1.14K$115.58−$132.2K−1.5%76.8K after
Mar 3, 2026 (view filing)Mar 21 dayMoreland Mary KEXECUTIVE VICE PRESIDENTSSaleCommon shares without par value−613$115.58−$70.9K−0.6%104.3K after

Top 10 13F holders, Q2 2026

The largest institutional positions in Abbott Laboratories at the end of Q2 2026; share changes are against Q1 2026.

See all 2,985 holders
Institutions holding ABT in Q2 2026
InstitutionSharesValue% of portfolioChange in sharesAction
BlackRock, Inc.152,563,476$13.8B0.21%+6,876,018+4.7%Added
Vanguard Capital Management LLC113,750,994$10.3B0.22%+801,061+0.7%Added
State Street Corp80,926,234$7.34B0.22%+1,350,766+1.7%Added
Charles Schwab Investment Management Inc59,674,507$5.41B0.72%+14,174,452+31.2%Added
Vanguard Portfolio Management LLC49,017,866$4.45B0.20%+1,072,975+2.2%Added
Geode Capital Management, LLC39,219,337$3.54B0.19%+70,542+0.2%Added
Capital Research Global Investors36,908,990$3.35B0.47%−12,866,372−25.8%Reduced
Capital International Investors34,654,113$3.15B0.65%−2,844,114−7.6%Reduced
Morgan Stanley26,611,315$2.41B0.13%−3,490,281−11.6%Reduced
Norges Bank23,354,911$2.12B0.21%+23,354,911New